The FDA has approved vepoligroty for the U.S. market under the brand name Lumvoa, targeting thyroid eye disease (TED) in adults. TED is an autoimmune condition often linked to Graves’ disease that causes inflammation and swelling around the eyes, leading to pain, double vision, and sometimes bulging eyeballs. Lumvoa works by blocking the IGF-1R receptor. […]